5-[(4-苯胺基-5-磺基萘基)偶氮]-4-羟基萘-2,7-二磺酸 | 7488-76-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-[(4-苯胺基-5-磺基萘基)偶氮]-4-羟基萘-2,7-二磺酸
• 英文名称: coomassie brilliant blue R-250
• 英文别名: coomassie blue；acid blue 92；4-(4-anilino-5-sulfo-[1]naphthylazo)-5-hydroxy-naphthalene-2,7-disulfonic acid；4-(4-Anilino-5-sulfo-[1]naphthylazo)-5-hydroxy-naphthalin-2,7-disulfonsaeure；4'-Anilino-8-hydroxy-[1.1']azonaphthalin-trisulfonsaeure-(3.6.5')；5-[(4-anilino-5-sulfonaphthyl)azo]-4-hydroxynaphthalene-2,7-disulfonic acid；Anazolene；4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid
• CAS: 7488-76-8
• 化学式: C₂₆H₁₉N₃O₁₀S₃
• 分子量: 629.649
• InChiKey: QFVHZQCOUORWEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  245
• 氢给体数：
  5
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  5-[(4-苯胺基-5-磺基萘基)偶氮]-4-羟基萘-2,7-二磺酸 在 potassium metaperiodate 作用下， 以 水 为溶剂， 生成 乙酰胺 、 N-甲基甲酰胺 、 溶剂黄146 、 邻苯二甲酸
  参考文献：
  名称：

  Development of an empirical kinetic model for sonocatalytic process using neodymium doped zinc oxide nanoparticles

  摘要：

  The degradation of Acid Blue 92 (AB92) solution was investigated using a sonocatalytic process with pure and neodymium (Nd)-doped ZnO nanoparticles. The nanoparticles were characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), and X-ray photoelectron spectroscopy (XPS). The 1% Nd-doped ZnO nanoparticles demonstrated the highest sonocatalytic activity for the treatment of AB92 (10 mg/L) with a degradation efficiency (DE%) of 86.20% compared to pure ZnO (62.92%) and sonication (45.73%) after 150 min. The results reveal that the sonocatalytic degradation followed pseudo-first order kinetics. An empirical kinetic model was developed using nonlinear regression analysis to estimate the pseudo-first-order rate constant (k(app)) as a function of the operational parameters, including the initial dye concentration (5-25 mg/L), doped-catalyst dosage (0.25-1 g/L), ultrasonic power (150-400 W), and dopant content (1-6% mol). The results from the kinetic model were consistent with the experimental results (R-2 = 0.990). Moreover, DE% increases with addition of potassium periodate, peroxydisulfate, and hydrogen peroxide as radical enhancers by generating more free radicals. However, the addition of chloride, carbonate, sulfate, and t-butanol as radical scavengers declines DE%. Suitable reusability of the doped sonocatalyst was proven for several consecutive runs. Some of the produced intermediates were also detected by GC-MS analysis. The phytotoxicity test using Lemna minor (L. minor) plant confirmed the considerable toxicity removal of the AB92 solution after treatment process. (C) 2015 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ultsonch.2015.09.004

文献信息

• Methods for treating and preventing sepsis using modified C1 inhibitor or fragments thereof
  申请人：Davis E. Alvin

  公开号：US20050288218A1

  公开（公告）日：2005-12-29

  The present invention is based, at least in part, on the discovery that the amino terminal domain and the N-linked carbohydrate contained in the amino terminal of C1INH are required for binding of C1INH to LPS. C1INH has the ability to block the binding of LPS to cells, e.g., macrophages. One aspect of the invention provides a method for treating or preventing sepsis in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby treating or preventing sepsis in a subject. In another aspect, the invention provides a method for treating or preventing LPS-mediated inflammation in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby treating or preventing LPS-mediated inflammation in a subject. In yet another aspect, the invention provides a method for suppressing the release of LPS-induced TNF-α in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby suppressing the release of LPS-induced TNF-α in a subject.

  本发明至少部分基于发现，C1INH的氨基末端结构域和氨基末端的N-连接糖基是C1INH与LPS结合所必需的。C1INH具有阻止LPS与细胞(例如巨噬细胞)结合的能力。本发明的一个方面提供了一种治疗或预防感染性休克的方法，该方法包括向受试者施用包含改良的C1INH多肽的有效量的组合物，从而治疗或预防感染性休克。在另一个方面，本发明提供了一种治疗或预防LPS介导的炎症的方法，该方法包括向受试者施用包含改良的C1INH多肽的有效量的组合物，从而治疗或预防LPS介导的炎症。在另一个方面，本发明提供了一种抑制LPS诱导的TNF-α释放的方法，该方法包括向受试者施用包含改良的C1INH多肽的有效量的组合物，从而抑制LPS诱导的TNF-α释放。
• ANTIGENIC COMPLEX FOR THE DIAGNOSIS AND TREATMENT OF PORPHYROMONAS GINGIVALIS INFECTION
  申请人：REYNOLDS ERIC CHARLES

  公开号：US20110081358A1

  公开（公告）日：2011-04-07

  The present invention provides a purified multimeric complex from P. gingivalis . The complex comprises at least one domain from each of RgpA, Kgp and HagA, and has a molecular weight greater than about 300 kDa.

  本发明提供了从牙龈炎梭菌中纯化的多聚复合物。该复合物包含来自RgpA、Kgp和HagA的至少一个结构域，分子量大约大于300千道尔顿。
• MUTATED SUMO ISOFORMS AND USES THEREOF
  申请人：Galisson Frédéric

  公开号：US20120276529A1

  公开（公告）日：2012-11-01

  Disclosed herein are substantially pure nucleic acids encoding mutated SUMO isoforms, polypeptides, vectors, cells and methods of their use to identify and quantify protein SUMOylation in mammalian cells. Also disclosed is a dual affinity method for detecting a mutated SUMOylated protein substrate fragment.

  本文公开了编码突变SUMO亚型的基本纯净核酸、多肽、载体、细胞及其使用方法，用于鉴定和定量哺乳动物细胞中的蛋白质SUMO化。还公开了一种双亲和力方法，用于检测突变的SUMO化蛋白底物片段。
• Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection
  申请人：Reynolds Eric Charles

  公开号：US08765144B2

  公开（公告）日：2014-07-01

  The present invention provides a purified multimeric complex from P. gingivalis. The complex comprises at least one domain from each of RgpA, Kgp and HagA, and has a molecular weight greater than about 300 kDa.

  本发明提供了从牙龈炎梭菌中纯化出的多聚复合物。该复合物包含来自RgpA、Kgp和HagA的至少一个结构域，并具有大约300 kDa以上的分子量。
• Antigenic Complex for the Diagnosis and Treatment of Porphyromonas Gingivalis Infection
  申请人：Reynolds Eric Charles

  公开号：US20090169568A1

  公开（公告）日：2009-07-02

  The present invention provides a purified multimeric complex form P. gingivalis . The complex comprises at least one domain from each of RgpA, Kgp and HagA, and has a molecular weight greater than about 300 kDa.

  本发明提供了一种纯化的P. gingivalis多聚复合物形式。该复合物包括来自RgpA、Kgp和HagA中至少一个域，并且分子量大约大于300 kDa。